Supplementary Figure 3 from The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells

PDF file - 797K, Positive and Negative controls for the immunohistological detection of the indicated antigens in adjacent cryosections of an inflammatory tonsil

Supplementary Figure Legends 1-6 from The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells

PDF file - 418K, Immunohistological detection of the indicated antigens in adjacent cryosections of cutaneous melanoma metastasis T9

PDF file - 37K, Main characteristics of patients and tumor samples

PDF file - 131K, Procedure for the preparation of immunoglobulin VDJC1 libraries

PDF file - 49K, List and principal characteristics of antibodies and oligonucleotide primers used in the study

PDF file - 4.3MB, Immunohistological detection of the indicated antigens in adjacent cryosections of primary melanoma T33

Female mice of inbred strain CBA do not reject syngeneic male skin grafts even though they mount a T-cell response against the male-specific HY antigen. We show that local immunostimulation performed by injecting cytokines and Toll-like receptor ligands in close vicinity to the graft causes rejection. We feel that this approach should be tested in tumor-bearing human patients in combination with antitumor vaccination. Relief of intratumor immunosuppression may increase considerably the fraction of patients who respond to vaccination directed against tumor antigens recognized by T cells.

In this Timeline, we describe the characteristics of tumour antigens that are recognized by spontaneous T cell responses in cancer patients and the paths that led to their identification. We explain on what genetic basis most, but not all, of these antigens are tumour specific: that is, present on tumour cells but not on normal cells. We also discuss how strategies that target these tumour-specific antigens can lead either to tumour-specific or to crossreactive T cell responses, which is an issue that has important safety implications in immunotherapy. These safety issues are even more of a concern for strategies targeting antigens that are not known to induce spontaneous T cell responses in patients.